You are here

Biosimilar Ruxience Approved for Some Blood Cancers and Autoimmune Conditions

May Be Used in Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Polyangiitis

The FDA has approved rituximab-pvvr (Ruxience, Pfizer), a rituximab biosimilar (Rituxan), for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.

Rituximab-pvvr is a mAb biosimilar to Rituxan that targets the protein CD20, which is present on the surface of B cells. When it attaches to CD20, rituximab helps destroy the B cells.

The approval was based on a review of data demonstrating rituximab-pvvr’s biosimilarity to the reference product, including results from the REFLECTIONS B3281006 clinical comparative study. The study evaluated the efficacy, safety and immunogenicity, pharmacokinetics, and pharmacodynamics of rituximab-pvvr.

The most common side effects reported in patients treated with rituximab-pvvr are infusion-related reactions, fever, lymphopenia, neutropenia, chills, infection, weakness, nausea, diarrhea, headache, muscle spasms, anemia, and peripheral edema.

Source: Centers for Biosimilars and Healio, July 23, 2019

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs